Drugs / CD19-TriCAR-T
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03910842 | Mar 2019 → Apr 2022 | leukemia, non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT03790891 | Jan 2019 → Jun 2021 | non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03720496 | Nov 2018 → Jun 2021 | B-cell non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-TriCAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03790891 ↗ |
| Modality | Cell therapy | “autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy” NCT03720496 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT03720496 ↗ |
| Target | CD19 | “targeting the CD19 positive NHL cells” NCT03720496 ↗ |